tbuckley/cabot-search huggingface dataset:
Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets).
Authors: Jonathan Wade Goldman, Lucio Crino, Everett E. Vokes, Esther Holgado, Karen L. Reckamp, Adam Pluzanski, David R. Spigel, Martin Kohlhaeufl, Marina Chiara Garassino, Laura Quan Man Chow, Scott N. Gettinger, David E. Gerber, Libor Havel, Suresh S. Ramalingam, Grace K. Dy, William J. Geese, Ang Li, Anne Blackwood-Chirchir, Diane I. Healey, Julie R. Brahmer
Journal: Journal of Clinical Oncology (2016)

9038 Background: CNS mets occur in 20%–40% of pts with adv NSCLC and are associated with poor overall survival (OS; median ≈7 mo). We evaluated nivo in this subgroup by: 1) pooling nivo-treated pts with adv NSCLC and pretreated (pretx) stable CNS mets at baseline (BL) across CheckMate 063 (phase [ph] II), 017 (ph III), and 057 (ph III); and 2) comparing OS with nivo vs docetaxel (doc) in pts with stable BL CNS mets in CheckMate 017 and 057. Methods: 1) Nivo-treated pts with adv NSCLC and pretx BL CNS mets from CheckMate 063 (n = 3), 017 (n = 9), and 057 (n = 34) were pooled to assess BL characteristics, safety, and CNS progression. 2) OS was analyzed in pts with pretx BL CNS mets and squamous (SQ; CheckMate 017) or non-SQ (NSQ; CheckMate 057) NSCLC treated with nivo 3 mg/kg Q2W vs doc 75 mg/m2 Q3W. Results: Of 46 nivo-assigned pts with pretx CNS mets, 74% had prior CNS-site radiotherapy and 85% had ≥ 2 extra-CNS sites of mets. Median follow-up was 8.4 mo (range: 0.3, 23.4); median treatment duration (n = 45; 1 pt not treated) was 2.3 mo (range: 0.03, 23.3). Any grade (gr) treatment-related (TR) adverse events (AEs) occurred in 67% of pts; gr 3–4 TRAEs occurred in 7%, with no TR deaths. CNS TRAEs occurred in 5 pts (11%) and were all gr 1–2 (paresthesia, n = 2; dizziness, somnolence, and tremor, n = 1 each). At time of overall disease progression (PD) or last tumor assessment, 33% of pts had no evidence of CNS progression (stable/decreased CNS lesions) and 52% had unequivocal progression in the CNS (15% had no post-BL CNS assessment). In pts with pretx CNS mets from CheckMate 017, median OS (events, n; HR) with nivo (n = 9) vs doc (n = 8) was 4.99 mo vs 3.86 mo (6 vs 8; not determined); in CheckMate 057, median OS with nivo (n = 34) vs doc (n = 34) was 7.61 mo vs 7.33 mo (30 vs 27; 1.04, 95% CI: 0.62, 1.76). Conclusions: Nivo was well-tolerated in pts with adv NSCLC and pretx CNS mets, with generally low-grade toxicities. One-third of pts had no evidence of CNS progression at time of PD/last assessment. In pts with SQ and NSQ NSCLC with pretx CNS mets, median OS was similar with nivo vs doc. Additional results (including OS and CNS progression rates in pts with/without pretx CNS mets and safety/efficacy of nivo in pts with untreated BL CNS mets from CheckMate 012) will be presented. Clinical trial information: NCT01721759; NCT01642004; NCT01673867.
Prognostic Value of Immunophenotype Analysis in Patients with Acute Promyelocytic Leukemia (APL) Treated with All-Transretinoic Acid and Anthracyclin Monochemotherapy.
Authors: Pau Montesinos, Concepcion Rivas, Consuelo Rayon, Edo Vellenga, Javier de la Serna, Juan Bergua, Ricardo Parody, Salud Brunet, Gustavo Milone, Miguel Sanz
Journal: Blood (2006)
GW27-e0621 Angiopoietin-2 as a biomarker for patients with Cardiac Syndrome X
Authors: Yousef Rasmi, Elmira Roshani-Asl, MohamadHasan KhademAnsari, MirHosein SeyedMohammadza, Alireza Rostamzadeh
Journal: Journal of the American College of Cardiology (2016)
Foresight Infectious Diseases China Project - A novel approach to anticipating future trends in risk of infectious diseases in China: methodology and results from an initial application
Authors: A Nicoll, J Huang, Z Xie, Collective the Foresight China Project Group
Journal: Eurosurveillance (2009)

The project devised a simple but novel methodology for identifying possible future trends in infectious diseases in animals and humans in China, of priority concern to the Chinese authorities. It used a model of disease drivers (social, economic, biological or environmental factors that affect disease outcomes, by changing the behaviour of diseases, sources or pathways) devised for the Foresight Programme in the United Kingdom. Nine families of drivers were adapted to Chinese circumstances and matrices were constructed to identify the likely relationship of single infectious diseases or families of diseases to the drivers. The likely future trends in those drivers in China were determined by interviews with 36 independent Chinese experts. These trends included not only potentially adverse animal and human movements but also opportunities for innovative surveillance methods, more use of hospitals, antimicrobials and vaccines. Some human behaviours and social trends were expected to increase the risk of infections (in particular sexually transmitted and healthcare-associated infections) while at the same time the experts thought the awareness of risk in the Chinese population would increase. The results suggested a number of areas where the Chinese authorities may experience difficulties in the future, such as rising numbers of healthcare-associated infections, zoonoses and other emerging diseases and sexually transmitted infections (including HIV). Not making firm predictions, this work identifies priority disease groups requiring surveillance and consideration of countermeasures as well as recommending strengthening basic surveillance and response mechanisms for unanticipatable zoonoses and other emerging disease threats.
TCT-608 Comparison of stent design on early outcome in patients undergoing primary percutaneous coronary intervention. Insights from large, multicenter, registry
Authors: Piotr P. Buszman, Krzysztof P. Milewski, Marek Gierlotka, Włodzimierz Grocholewski, Aleksander Zurakowski, Marek Krol, Marek Kondys, Janusz Prokopczuk, Bogdan Gorycki, Buszman E. Pawel
Journal: Journal of the American College of Cardiology (2015)
Survival following partial pancreatectomy and radiation for ampullary adenocarcinoma
Authors: J. C. Haynes, D. Moghanaki, A. Morgans, P. Salmon, E. E. Furth, B. J. Giantonio, J. Drebin, E. F. Rosato, R. Whittington, J. M. Metz
Journal: Journal of Clinical Oncology (2008)

15614 Background: AA remains a relatively rare cancer with limited information regarding optimal management. Very few series of AA treated with postoperative CRT have been reported. This retrospective study reports the outcomes of adjuvant chemotherapy and radiation therapy from a single institution. Patients and Methods: We identified 20 patients with AA who completed a course of 5FU based postoperative chemoradiation at the Hospital of the University of Pennsylvania between 1989 and 2005. All patients underwent a Whipple-style partial pancreatectomy prior to radiation, of which 14 had a pylorus-preserving procedure. All patients treated had either pathologic T3, T4, or N1 involvement, or microscopically positive margins. There were no patients with gross residual or metastatic disease. 5FU-based CRT was delivered to the surgical bed and regional nodes with a mean dose of 49.5 Gy (range 43.2 to 59.4). The median age at completion of radiation was 63 years (range 43-78). Survival was calculated by Kaplan-Meier actuarial analysis. Results: Median follow-up is 1.2 years (range: 0.2-9.9 years). Actuarial survival at 1, 2, and 3 years was 56%, 51%, and 39% respectively with 11, 10, and 6 patients evaluable at those time points. There were 3 patients with pT4 and 11 with pT3 involvement. Fifteen had positive nodes on with a median of 14 nodes sampled. Three patients had microscopically positive margins. Conclusions: This series contributes additional data to the limited literature available on outcomes for ampullary carcinoma following resection and chemoradiation. Pts with ampullary carcinoma have a favorable outcome compared to pancreatic and biliary carcinomas. Postoperative chemotherapy and radiation therapy should be considered for high risk disease. No significant financial relationships to disclose.
Outcome of Patients with Myelodysplastic Syndromes (MDS) Undergoing Allogeneic Myeloablative Transplantation: A Retrospective Analysis Comparing HLA Matched Unrelated Donor Bone Marrow Transplantation (BMT) to HLA Identical Sibling SCT. A Retrospective Study on Behalf of the EBMT - Chronic Leukemia Working Party.
Authors: Ph. Guardiola, W. Fibbe, T. Ruutu, L. Verdonck, U.W. Schaefer, E. Gluckman, G. Verhoef, J.J. Cornelissen, E. Carreras, N.H. Russel, D. Selleslag, A. Vitek, F. Locatelli, E. Alessandrino, H. Schouten, A. van Biezen, R. Brand, D. Niederwieser, T.M. de Witte
Journal: Blood (2004)
Second line therapy with cetuximab in NSCLC
Authors: R. Buosi, A. Gatti, S. Carnio, A. Sponghini, C. Olympios, O. Alabiso
Journal: Journal of Clinical Oncology (2006)

17145 Background: EGFR is overexpressed in different solid tumors and in 50–80% of NSCLC. The neoplastic growth and metastatic process is correlated with EGFR overexpression, so that it became the target of a new therapeutic approach. The monoclonal antibody (Mab) against the extracellular domain represent the most innovated method of EGFR inaction. Methods: From May to October 2005 10 patients (8 M and 2 F) of median age 62 years with NSCLC in stage IIIB-IV (7 adenocarcinomas and 3 squamocellulars) have been treated with the association of chemotherapy and Cetuximab. All patients presented a strumental PD after a first line of platinum-based chemotherapy. At the basic valuation, 7 presented ECOG 0 and 3 ECOG 1. Before treatment EGFR expression has been valued by immunohistochemical analysis. Carboplatinum AUC6 + Paclitaxel 175 mg/mq D1 every 3 weeks was chosen as schedule in 5 patients, Paclitaxel 80 mg/mq/w (4/6 weeks) administered in 3 patients while Vinorelbine 25 mg/mq D1, 8 every 3 weeks administered in 2 patients with moderated cardiac disease. All patients received Cetuximab 400 mg/mq at first week followed by 250 mg/mq weekly until PD. Results: Till now 7 patients valued for OR after three months of treatment: 1 RC, 3 RP, 1 SD, 2 PD; none presented an ECOG worsening. Gr 4 hematological toxicity with febrile neutropenia registered in 1 patient treated with vinorelbine. Alopecia reported in all patients treated with paclitaxel and Gr 3 neurotoxicity reported in 1 patient. No other Gr &gt; 2 toxicity has been registered. Skin rash has been checked in all patients. Conclusions: according to our experience the administration of Cetuximab seems to be well tolerated and does not modify the chemotherapy toxicity profile. The combination with vinorelbine is the most toxic. At the moment our data do not allow us to express any judgment on the treatment efficacy, but till today all patients are alive and only one of them presents clinical signs of PD. No significant financial relationships to disclose.
Procalcitonin in Crohn's disease with fever episodes, a variable to differentiate intra-abdominal abscess from disease flares
Authors: Xiaolong Ge, Dong Hu, Yu Cao, Zhijian Liu, Chao Ding, Hongliang Tian, Jianfeng Gong, Weiming Zhu, Ning Li, Jieshou Li
Journal: International Journal of Surgery (2016)
TCT-99 Valve thrombosis after transcatheter aortic valve replacement: incidence, characteristics and outcomes
Authors: John Jose Erungaren, Dmitriy S. Sulimov, Mohamed El-Mawardy, Takao Sato, Abdelhakim Allali, Martin Landt, Bettina Schwarz, Gert Richardt, Mohamed Abdel-Wahab
Journal: Journal of the American College of Cardiology (2015)
NHL risk in HIV+ adults on antiretroviral therapy in four continents.
Authors: Eliane Rohner, Lukas Buetikofer, Mhairi Maskew, Valeria Fink, Beatriz Grinsztejn, Chad Achenbach, James J. Goedert, Julia Bohlius
Journal: Journal of Clinical Oncology (2016)

1578 Background: The risk of developing Non-Hodgkin lymphoma (NHL) has not been compared between continents with different HIV epidemics. Methods: We analyzed HIV+ adults (≥16 years) starting combined antiretroviral therapy (ART) after 1995 from the International Epidemiologic Databases to Evaluate AIDS and Collaboration of Observational HIV Epidemiological Research in Europe in EuroCoord. We estimated incidence rates and compared the risk of developing NHL between continents using flexible parametric survival models, adjusted for age, sex, mode of infection, current CD4 count, CDC stage, ART regimen and ART start year. Results: We included 210,178 adults from Europe, Southern Africa, Latin and North America. Median age at ART start was 37 years and similar across regions (Table). Median CD4 count at ART start was <200 cells/µL in Latin America and Southern Africa and >200 cells/µL in Europe and North America. During 1.1 million person-years (PY) 1,598 patients developed NHL. Within 2 years after ART start incidence rate per 100,000 PY (95% CI) was 298 (278-319) in Europe, 136 (101-185) in Southern Africa, 235 (168-327) in Latin America and 368 (304-444) in North America. Two years after ART start the risk of developing NHL was similar in patients from Latin America and Southern Africa compared to Europe in crude and adjusted analyses. In North America the risk of developing NHL compared to Europe was increased in crude analysis (hazard ratio (HR) 1.72, 95% CI 1.46-2.03), but not in adjusted analyses (HR 1.11, 95% CI 0.84-1.45). The change was mainly due to adjustment for current CD4 counts. Conclusions: Despite ART, NHL rates remain high in HIV+ adults. The risk of developing NHL was similar in Europe, Southern Africa and Latin America. Compared to Europe, NHL risk was higher in North America, which was mainly explained by lower current CD4 counts in these patients. Characteristics of included adults by region. Southern Africa Latin America North America Europe N 22,149 8,710 17,001 162,318 Age at ART start* [years] 36 (31-43) 36 (30-43) 40 (34-46) 37 (31-45) CD4 at ART start* [cells/μl] 107 (43-176) 165 (61-273) 233 (92-378) 250 (126-368) Women 63% 26% 25% 27% Heterosexual men 31% 23% 19% 28% MSM NR 42% 51% 40% *Median with interquartile range.
Reduced-Intensity Unrelated Cord-Blood Transplantation (RI-UCBT) for Patients with High-Risk Myeloid Malignancies.
Authors: Koichiro Yuji, Shigesaburo Miyakoshi, Shinsuke Takagi, Daisuke Kato, Yuji Miura, Hiroto Narimatsu, Eiji Kusumi, Yukiko Kishi, Tomoko Matsumura, Kazuhiro Kobayashi, Tamae Hamaki, Naoyuki Uchida, Masahiro Kami, Kazuhiro Masuoka, Naoko Murashige, Atsushi Wake, Junichi Ueyama, Akiko Yoneyama, Michio Matsuzaki, Shinichi Morinaga, Yoshitomo Muto, Yoichi Takaue, Shuichi Taniguchi
Journal: Blood (2005)
The Interaction of CXCR4/SDF-1 and VLA-4 Regulates Adhesion and Transendothelial Migration in Waldenstrom Macroglobulinemia.
Authors: Hai T. Ngo, Mena Farag, Xavier Leleu, Xiaoying Jia, Judith Runnels, Anne-Sophie Moreau, Abdelkareem Azab, Feda Azab, Evdoxia Hatjiharissi, Aldo Roccaro, Antonio Sacco, Irene M. Ghobrial
Journal: Blood (2007)
Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) (INFORM; C-TONG 0804).
Authors: L. Zhang, M. Shenglin, X. Song, B. Han, Y. Cheng, C. Huang, S. Yang, X. Liu, L. Yun-Peng, M. Wang, X. Zhang
Journal: Journal of Clinical Oncology (2011)

LBA7511 The full, final text of this abstract will be available in Part II of the 2011 Annual Meeting Proceedings, distributed onsite at the Meeting on June 4, 2011, and as a supplement to the June 20, 2011, issue of Journal of Clinical Oncology.
TCT-774 Safety and Performance of the EnligHTN™ Renal Denervation System in Patients with Drug-resistant Hypertension: Pooled analyses from the EnligHTN I, II and III trials
Authors: Stephen G. Worthley, Joseph Montarello, Manish Saxena, Ajay Jain, Darren Walters, Matthew W. Pincus, Konstantinos P. Tsioufis, Vasilios Papademetriou, Mel Lobo
Journal: Journal of the American College of Cardiology (2015)
Functional Activity of Granulocytes Primed In Vivo with Glycosylated Granulocyte Colony-Stimulating Factor (G-CSF) Is Superior To Priming with Non-Glycosylated G-CSF.
Authors: Daniel Ribeiro, Stephanie Laufs, Marlon R. Veldwijk, Jens W. Zeller, Anthony D. Ho, Stefan Fruehauf
Journal: Blood (2005)
TCT-39 Diagnostic ability of contrast medium induced fractional flow reserve to assess functional lesion severity of coronary artery stenosis
Authors: Hiroaki Takashima, Akihiro Suzuki, Katsuhisa Waseda, Yuki Saka, Akiyoshi Kurita, Hirohiko Ando, Kazuyuki Maeda, Shinichiro Sakurai, Yoshinori Nishikawa, Tetsuya Amano
Journal: Journal of the American College of Cardiology (2015)
Dependency of Survival on Additional Karyotype Anomalies and Bone Marrow Blast Count in Patients Suffering from Myelodysplastic Syndromes with 5q Deletion.
Authors: Sabine Knipp, Barbara Hildebrandt, Martine Jotterand, Marc Schapira, Aristoteles Giagounidis, Norbert Gattermann, Carlo Aul, Ulrich Germing
Journal: Blood (2007)
Reduced levels of IGF-1 decrease tumor burden in an orthotopic mouse model of pancreatic cancer
Authors: L. Lashinger, L. Malone, E. Daniels, N. Smith, A. Pavone, J. K. Colby, S. Perkins, S. M. Fischer, S. D. Hursting
Journal: Journal of Clinical Oncology (2008)

1504 Background: Pancreatic cancer is the 4th leading cause of cancer death in both men and women in the U.S. Increased obesity has emerged as a risk factor for pancreatic cancer. Calorie restriction (CR), a dietary strategy that prevents or reverses obesity, has significant anti-cancer effects in a variety of tumor types and in both spontaneous and chemically-induced tumors. We have found in the K5.COX-2 transgenic mouse model of pancreatitis-driven pancreatic cancer that CR significantly protects from spontaneous pancreatic lesion formation as compared to the overweight and obese groups. Also, CR mice had significantly reduced serum IGF-1 levels and pro-inflammatory cytokine levels as compared to ad libitum fed (AL) and high fat (HF) fed mice. We hypothesized that decreased serum IGF-1 levels were responsible for the decreased tumor burden. Methods: Orthotopic injections were performed on 6–8 week old Liver-specific IGF-1- Deficient (LID) and control mice (FVB/N and floxed IGF-1) with pancreatic tumor cells (JC101) derived from a transgenic K5.COX-2 animal. Tumors and pancreata were harvested and weighed 28 days after tumor injection. Results: LID mice exhibited significantly reduced tumor burden (0.23±0.04) than either the floxed IGF-1 control (0.71±0.10) or FVB/N wild-type animals (0.71±0.04) following 28 days of growth. In addition to a reduction in serum IGF-1 in the LID mice, we also found a substantial decrease in serum levels of a panel of pro-inflammatory cytokines such as IFN-g, IL-1b, IL-4, IL-5, IL-10, IL-12, and TNF-a as compared to sera of control animals. Furthermore, we saw reduced proliferation and microvessel density in the tumor tissue of LID animals compared to controls by immunohistochemical staining. Conclusions: Using a model of pancreatitis-induced or orthotopically injected pancreatic tumorigenesis, our findings indicate that either transgenic manipulation or diet modulation of serum IGF-1 can alter the development of pancreatic cancer. Moreover, our findings suggest a strong link between expression of IGF-1 and pro-inflammatory cytokines in response to CR and the prevention of tumor growth. This could have direct implications for the prevention and control of pancreatic tumors due to chronic inflammation and/or obesity. No significant financial relationships to disclose.
TCT-75 Cangrelor Improves Ischemic Outcomes In Patients With Multivessel Disease And Single Vessel Disease Undergoing PCI: Insights From The CHAMPION PHOENIX Trial
Authors: Freddy Abnousi, Vandana Sundaram, Jayne Prats, Efthymios N. Deliargyris, Gregg W. Stone, Christian Hamm, Philippe G. Steg, C. Michael Gibson, Harvey D. White, Matthew J. Price, Celina Yong, Manisha Desai, Robert Harrington, Deepak L. Bhatt, Kenneth Mahaffey
Journal: Journal of the American College of Cardiology (2015)
Sixty seconds on . . . night shifts
Authors: Anne Gulland
Journal: BMJ (2016)

This is worth staying awake for. New research has shown that working nights is not, after all, linked to an increased risk of breast cancer. Prospective studies of nearly 800 000 UK women, combined with other findings, showed that women who worked nights (including those who had worked nights for 20 to 30 years) were no more likely to develop breast cancer …
TCT-527 Long-term Clinical Outcomes of Patients Treated With The Everolimus-eluting Bioresorbable Vascular Scaffold. The BVS Expand Study
Authors: Cordula Felix, Jiang-Ming Fam, Yoshinobu Onuma, Yuki Ishibashi, Bert Everaert, Roberto Diletti, Evelyn Regar, Nicolas M. Van Mieghem, Joost Daemen, Peter De Jaegere, Felix Zijlstra, Robert J. Van Geuns
Journal: Journal of the American College of Cardiology (2015)
Chemotherapy dose adjustment after severe toxicity in older cancer patients
Authors: C. A. O’Leary, M. Extermann
Journal: Journal of Clinical Oncology (2008)

9627 Background: About 60% of older cancer patients experience a grade 4 hematologic (G4H) toxicity and/or a grade 3–4 non- hematologic (G3–4NH) toxicity from chemotherapy. Yet, the mean dose intensity of their treatment is 90% (Extermann et al., 2002). This suggests that oncologists might use alternative strategies to dose reduction. No data exist as to the safety of these alternative strategies. Methods: We reviewed the data from 2 prospective studies of tolerance to chemotherapy in older patients. The dose modifications were left at the discretion of the physicians. Toxicity data were prospectively collected for up to 6 months and rated with CTC 3.0. We assessed whether the treatment was modified in response to G4H, G3–4NH, or either (severe toxicity). We assessed what the modification was, whether patients experienced subsequent severe toxicity, and the reason for stopping treatment. Results: In our sample of 205 patients (age 70- 92, median 75), 72% had a severe toxicity: 35% G4H, 59% G3–4NH, and 24% both. Treatment was modified in 59% of patients with G4H, 56% with G3–4NH, and 57% with both. A modification was made for 85 patients: 22 interruptions of treatment, 25 dose reductions, 13 delays without dose reduction, 21 modified regimens, 3 additional anti-emetics, 2 prophylactic anti-infectious agents, 1 addition of G-CSF, and 1 potassium replacement. Subsequently, 37% of patients who had a modification experienced further severe toxicity, versus 14% of the patients who did not have a modification (p<0.002). Baseline age, sex, BMI, tumor stage, comorbidity, depression, and functional, nutritional, or cognitive status had little or no correlation with the decision to modify the treatment. Conclusions: Most older cancer patients experience a severe toxicity from their chemotherapy. Yet, 2 out of 5 do not undergo chemotherapy modification after it. Oncologists appeared able to effectively identify patients in whom it was safe to continue a full-dose regimen, although this study could not identify clear explanatory mediators. Therefore, requiring a systematic dose reduction for severe toxicity in therapeutic trials and practice might lead to undertreatment of older cancer patients. Research to establish more nuanced treatment modification guidelines needs to be conducted. No significant financial relationships to disclose.
TCT-52 Response of Forward Stroke Volume Predict Clinical Outcomes and Echocardiographic Changes after Percutaneous Mitral Valve Repair with MitraClip System
Authors: Shunsuke Kubo, Takahiro Shiota, Yuji Itabashi, Yukiko Mizutani, Asma Hussaini, Emily Tat, Mamoo Nakamura, Alfredo Trento, Robert Siegel, Saibal Kar
Journal: Journal of the American College of Cardiology (2015)
TCT-683 Early Stroke After Implantation of a Self-Expanding Transcatheter Aortic Valve Prosthesis: Experience From the CoreValve Clinical Trials
Authors: Neal Kleiman, Brij Maini, Michael J. Reardon, Stanley Katz, James Kauten, Raymond G. McKay, Robert C. Hagberg, Jeffrey Popma
Journal: Journal of the American College of Cardiology (2015)